Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
44.79
+2.28 (5.36%)
Jan 30, 2025, 4:00 PM EST - Market closed
Janux Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Janux Therapeutics stock have an average target of 83.09, with a low estimate of 48 and a high estimate of 200. The average target predicts an increase of 85.51% from the current stock price of 44.79.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 11, 2024.
Analyst Ratings
The average analyst rating for JANX stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $200 | Buy | Reiterates | $200 | +346.53% | Dec 11, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $42 → $62 | Hold | Maintains | $42 → $62 | +38.42% | Dec 4, 2024 |
| Stifel | Stifel | Strong Buy Maintains $70 → $115 | Strong Buy | Maintains | $70 → $115 | +156.75% | Dec 3, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $79 → $91 | Buy | Maintains | $79 → $91 | +103.17% | Dec 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $63 → $70 | Strong Buy | Maintains | $63 → $70 | +56.28% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
11.29M
from 8.08M
Increased by 39.66%
Revenue Next Year
3.11M
from 11.29M
Decreased by -72.46%
EPS This Year
-1.39
from -1.32
EPS Next Year
-2.06
from -1.39
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 13.7M | 13.9M | 52.5M | |||
| Avg | 11.3M | 3.1M | 9.1M | |||
| Low | 10.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 68.9% | 22.8% | 1,588.6% | |||
| Avg | 39.7% | -72.5% | 191.5% | |||
| Low | 28.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.34 | -1.02 | -1.20 | |||
| Avg | -1.39 | -2.06 | -2.65 | |||
| Low | -1.58 | -3.66 | -6.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.